Gabriela C. Lobato's research while affiliated with Rush University Medical Center and other places

Publications (12)

Article
Background: Detection rates of early-stage lung cancer are traditionally low, which contributes to inconsistent treatment responses and high rates of annual cancer deaths. Currently, low-dose computed tomography (LDCT) screening produces a high false discovery rate. This limitation has prompted research to identify biomarkers to more clearly defin...
Preprint
Full-text available
Background: Detection rates of early-stage lung cancer are traditionally low, which contributes to inconsistent treatment responses and the highest rates of annual cancer deaths in the U.S. Currently, age and smoking history are the primary factors that qualify patients for low-dose computed tomography (LDCT) screening, which contributes heavily to...
Article
3054 Background: We previously reported associations of pretreatment serum biomarkers with clinical outcomes in a cohort of advanced NSCLC patients that progressed on front-line therapy. This study aims to elucidate mechanisms underlying cancer cachexia/ pre-cachexia by evaluating relationships between baseline serum biomarker values and sequential...
Article
Background: This study explores the potential diagnostic utility of soluble Human Leukocyte Antigen (sHLA) molecules differentially released by lung adenocarcinoma and benign lung lesions. Methods: Conditioned media from the NSCLC cell lines H358 and H1703 were immunoblotted for soluble isoforms of major histocompatibility complex (MHC) class I...
Article
Background: The objective of this study was to evaluate disease stage-associated differences in receptor tyrosine kinase (RTK) signaling in A549 cells using pretreatment sera from cases of pathologically-confirmed lung adenocarcinoma or control cases derived from a lung cancer screening study. This was accomplished as a means to explore the hypothe...
Article
Full-text available
Background: The objective of this study was to identify serum biomarkers capable of predicting clinical outcomes in previously-treated NSCLC patients with wild-type for EGFR activating mutations or insufficient tissue for mutation status determination. Methods: Sixty-six Luminex immunoassays representative of biological themes that emerged from...
Article
Introduction: Clinical outcomes for type II diabetes patients diagnosed with NSCLC are superior for those receiving metformin relative to other diabetic medications, though the mechanism for this effect remains incompletely elucidated. We hypothesized that metformin induces changes in Akt-based signaling via AMPK that increases glycolytic flux, and...
Article
Background Lung cancer is leading cause of cancer related deaths worldwide, with metastasis underlying this high mortality rate. An epithelial to mesenchymal transition (EMT) and angiogenesis are processes well known to increase tumor cell invasive potential. Transforming growth factor - beta (TGF-β) and insulin-like growth factor (IGF-1) are well...
Article
Background: Dysregulation of angiogenesis is known to be associated with tumorigenesis and metastatic progression in multiple carcinomas. The aim of this study was to evaluate the prognostic value of circulating angiogenesis biomarkers in lung adenocarcinoma progression. For that, we hypothesize that circulating levels of biomarkers characteristic...

Citations

... In the PhI trial, PK samples were taken before and at the end of the first cetuximab infusion, as well as at minimum cetuximab concentrations (C min ) until day 29. For the dosing interval starting on day 29, dense sampling ( Figure 1b) was performed as follows: patients receiving ADR (arm A) were sampled at the end of infusion and at 4, 24, 48, 96, and 168 hours after the start of infusion, whereas patients in other treatment groups (arm B) were sampled at the end of infusion and at 4,24,48,96,168,240, and 336 hours after the start of infusion. After the dense sampling interval, blood samples were collected at C min until the end of the study in both arms. ...
... MHC class II expression in peripheral blood was also analyzed in lung cancer patients. 34,[49][50][51][52] HLA-DR9 was found to have higher frequency in peripheral blood of lung cancer patients, while HLA-DR6 was found to have lower frequency in lung cancer patients than healthy controls by serological MHC typing. 34 Another study showed lung cancer patients with an increased HLA-DR (+) cells in peripheral blood had a poor prognosis. ...
... Peripheral blood was collected from all patients immediately prior to induction with the PD-1/-L1 directed immunotherapy and processed into serum using standard methods, as previously defined [29,30,32,33]. A portion of each serum sample used for the Luminex evaluations was supplemented with 25 μL/mL of the Mammalian Protease inhibitor cocktail (Sigma, St. Louis, MO) and 10 μL/mL of 0.5 M EDTA to minimize further proteolysis. ...
... Activated IGF-IR triggers numerous downstream signaling cascades, including SCiENTifiC RepoRts | (2018) 8:10119 | DOI:10.1038/s41598-018-27583-y mitogen-activated proteins Kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways that regulate carcinogenic transformation and growth of cancer cells [21][22][23] . Previous studies have implicated that IGF-1R was related to tumor regulation in many cancers, such as pancreatic cancer 24 , breast cancer 25,26 , lung cancer 27 and hepatocellular carcinoma 28 . ...
... TGFβ is a known inhibitor of cell cycle progression [18] and thus, functions as a tumor suppressor in the early stages of certain cancers. On the contrary, TGFβ signaling can be pro-tumorigenic by inducing genes that promote tumorigenic aspects of glioma progression such as angiogenesis [19], metastasis [20,21] and epithelialmesenchymal transition [22]. Hyperactive TGFβ signaling is associated with certain subtypes of glioblastoma tumors, such as the mesenchymal subset and contributes to aggressiveness of the tumor and poor prognosis in patients [23][24][25]. ...
... In particular, Park et al. [54] first reported that patients with low serum levels of Ang-2 exhibited a better overall survival compared to patients with higher levels of Ang-2. However, various research analyses followed without drawing definite conclusions [44,[55][56][57][58]. Notably, a recent meta-analysis reinforced the initial observation of Park et al. [54] supporting that Ang-2 exhibits strong prognostic value in both NSCLC and SCLC incidences [52]. ...